Fig. 6.

CML therapy regulates exosome release and exosomeinduced tube formation. a Effects of imatinib and dasatinib on K562 and HUVEC proliferation. Imatinib and dasatinib exposure continued for 24 or 48 h. b Both imatinib and dasatinib reduce total released exosomal protein. c Exosomes from imatinib- or dasatinib-treated K562 cells (0.1 µM, and 0.1 nM, respectively) are equipotent as those from vehicle-treated cells. d, e A dose-dependent inhibition by dasatinib (d), but not imatinib (e) on the HUVEC response to control exosomes. Data are mean ± SEM of triplicate experiments